IL320143A - Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents - Google Patents
Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agentsInfo
- Publication number
- IL320143A IL320143A IL320143A IL32014325A IL320143A IL 320143 A IL320143 A IL 320143A IL 320143 A IL320143 A IL 320143A IL 32014325 A IL32014325 A IL 32014325A IL 320143 A IL320143 A IL 320143A
- Authority
- IL
- Israel
- Prior art keywords
- mmol
- methyl
- mixture
- tert
- stirred
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/100542 WO2021026803A1 (en) | 2019-08-14 | 2019-08-14 | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| PCT/IB2020/057602 WO2021028854A1 (en) | 2019-08-14 | 2020-08-12 | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320143A true IL320143A (en) | 2025-06-01 |
Family
ID=72145436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320143A IL320143A (en) | 2019-08-14 | 2020-08-12 | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| IL289754A IL289754B2 (en) | 2019-08-14 | 2020-08-12 | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289754A IL289754B2 (en) | 2019-08-14 | 2020-08-12 | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11420970B1 (enExample) |
| EP (2) | EP4013755B1 (enExample) |
| JP (2) | JP7638960B2 (enExample) |
| KR (1) | KR102946008B1 (enExample) |
| CN (1) | CN114585622B (enExample) |
| AU (1) | AU2020328919B2 (enExample) |
| BR (1) | BR112022002520A2 (enExample) |
| CO (1) | CO2022002804A2 (enExample) |
| DK (1) | DK4013755T3 (enExample) |
| EC (1) | ECSP22019360A (enExample) |
| ES (1) | ES3023540T3 (enExample) |
| FI (1) | FI4013755T3 (enExample) |
| IL (2) | IL320143A (enExample) |
| MX (1) | MX2022001784A (enExample) |
| MY (1) | MY209614A (enExample) |
| PH (1) | PH12022550343A1 (enExample) |
| PL (1) | PL4013755T3 (enExample) |
| PT (1) | PT4013755T (enExample) |
| WO (2) | WO2021026803A1 (enExample) |
| ZA (1) | ZA202200519B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026803A1 (en) * | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| CN114981270B (zh) * | 2019-09-20 | 2024-10-18 | 诺华公司 | Mll1抑制剂和抗癌剂 |
| JP2025504379A (ja) * | 2022-01-05 | 2025-02-12 | ケイ３６・セラピューティクス・インコーポレイテッド | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 |
| JP2025508714A (ja) * | 2022-02-16 | 2025-04-10 | デューク ストリート バイオ リミテッド | 医薬化合物 |
| WO2023225144A1 (en) * | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225150A1 (en) * | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| JP2025517349A (ja) * | 2022-05-18 | 2025-06-05 | ケイ３６・セラピューティクス・インコーポレイテッド | ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用 |
| US20250326752A1 (en) * | 2022-05-18 | 2025-10-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250361235A1 (en) * | 2022-05-23 | 2025-11-27 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions |
| WO2023230038A1 (en) * | 2022-05-23 | 2023-11-30 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions |
| CN119894513A (zh) * | 2022-09-26 | 2025-04-25 | 德州大学系统董事会 | 作为nsd活性调节剂的杂环 |
| WO2024073283A1 (en) * | 2022-09-26 | 2024-04-04 | Board Of Regents, The University Of Texas System | Heterocycles as modulators of nsd activity |
| CN120641105A (zh) * | 2022-12-12 | 2025-09-12 | K36治疗股份有限公司 | 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途 |
| US20250011329A1 (en) * | 2023-06-21 | 2025-01-09 | K36 Therapeutics, Inc. | Substituted piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions |
| AU2024381513A1 (en) * | 2023-11-17 | 2026-06-04 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| CN117720550A (zh) * | 2023-12-14 | 2024-03-19 | 深圳市华先医药科技有限公司 | (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法 |
| CN117843641B (zh) * | 2023-12-28 | 2025-04-25 | 和径医药科技（上海）有限公司 | Nsd3抑制剂及其制备方法和应用 |
| IL330390A (en) * | 2024-01-02 | 2026-08-01 | K36 Therapeutics Inc | Methods and medicinal compounds inhibiting NSD2 for the treatment of cancers from the piperidinyl-methyl-purinamine family |
| CN118459395A (zh) * | 2024-05-10 | 2024-08-09 | 南通大学 | 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4331944B2 (ja) * | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
| US7332486B2 (en) * | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| CA2497765A1 (en) * | 2002-09-27 | 2004-04-08 | Sumitomo Pharmaceuticals Co., Ltd. | 8-hydroxy substituted adenine compounds and uses thereof |
| JP2004137157A (ja) * | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | 新規アデニン誘導体を有効成分として含有する医薬 |
| JP2007269629A (ja) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
| TW200902018A (en) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
| BR112012009329A2 (pt) * | 2009-10-22 | 2016-06-07 | Gilead Sciences Inc | derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia) |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2019196918A1 (zh) | 2018-04-13 | 2019-10-17 | 罗欣药业(上海)有限公司 | 五元杂环并嘧啶类化合物、药物组合物及用途 |
| CN109223794B (zh) * | 2018-08-24 | 2020-07-28 | 江苏理工学院 | 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用 |
| CN108853110B (zh) * | 2018-08-24 | 2020-07-28 | 江苏理工学院 | 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用 |
| WO2021026803A1 (en) * | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| JP2025504379A (ja) | 2022-01-05 | 2025-02-12 | ケイ３６・セラピューティクス・インコーポレイテッド | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 |
| WO2023225144A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| JP2025517349A (ja) | 2022-05-18 | 2025-06-05 | ケイ３６・セラピューティクス・インコーポレイテッド | ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用 |
| WO2023225150A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250326752A1 (en) | 2022-05-18 | 2025-10-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
-
2019
- 2019-08-14 WO PCT/CN2019/100542 patent/WO2021026803A1/en not_active Ceased
-
2020
- 2020-08-12 PL PL20757967.3T patent/PL4013755T3/pl unknown
- 2020-08-12 KR KR1020227008255A patent/KR102946008B1/ko active Active
- 2020-08-12 AU AU2020328919A patent/AU2020328919B2/en active Active
- 2020-08-12 JP JP2022509034A patent/JP7638960B2/ja active Active
- 2020-08-12 WO PCT/IB2020/057602 patent/WO2021028854A1/en not_active Ceased
- 2020-08-12 ES ES20757967T patent/ES3023540T3/es active Active
- 2020-08-12 EP EP20757967.3A patent/EP4013755B1/en active Active
- 2020-08-12 PT PT207579673T patent/PT4013755T/pt unknown
- 2020-08-12 PH PH1/2022/550343A patent/PH12022550343A1/en unknown
- 2020-08-12 CN CN202080069611.5A patent/CN114585622B/zh active Active
- 2020-08-12 IL IL320143A patent/IL320143A/en unknown
- 2020-08-12 IL IL289754A patent/IL289754B2/en unknown
- 2020-08-12 MY MYPI2022000244A patent/MY209614A/en unknown
- 2020-08-12 FI FIEP20757967.3T patent/FI4013755T3/fi active
- 2020-08-12 DK DK20757967.3T patent/DK4013755T3/da active
- 2020-08-12 MX MX2022001784A patent/MX2022001784A/es unknown
- 2020-08-12 BR BR112022002520A patent/BR112022002520A2/pt unknown
- 2020-08-12 EP EP25150251.4A patent/EP4559915A1/en active Pending
-
2021
- 2021-05-21 US US17/327,226 patent/US11420970B1/en active Active
-
2022
- 2022-01-11 ZA ZA2022/00519A patent/ZA202200519B/en unknown
- 2022-03-10 CO CONC2022/0002804A patent/CO2022002804A2/es unknown
- 2022-03-14 EC ECSENADI202219360A patent/ECSP22019360A/es unknown
- 2022-05-09 US US17/739,855 patent/US12312353B2/en active Active
-
2025
- 2025-02-19 JP JP2025024756A patent/JP2025081505A/ja active Pending
- 2025-05-20 US US19/213,478 patent/US20250276971A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4013755B1 (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| KR102337055B1 (ko) | 피롤로[1,2-b]피리딘 유도체 | |
| JP6242885B2 (ja) | ５−アザインダゾール化合物及び使用方法 | |
| KR20210152515A (ko) | 이카로스 및 아이올로스의 트리시클릭 분해제 | |
| JP2025515285A (ja) | 大環状複素環及びその使用 | |
| EP4291562B1 (en) | Thienopyrrole compounds | |
| CA3154136C (en) | MLL-1 INHIBITORS AND ANTICANCER AGENTS | |
| AU2021278156B2 (en) | MLL1 inhibitors and anti-cancer agents | |
| CA3144542C (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| HK40075573A (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| HK40075573B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| EA047083B1 (ru) | Пиперидинил-метил-пуринамины в качестве ингибиторов nsd2 и противораковых средств | |
| TW202434589A (zh) | 巨環雜環及其用途 | |
| HK40105012A (en) | Thienopyrrole compounds |